Biostock publishes article about the positive pre-clinical results and coming milestone for Prolight Diagnostics in Q2
Prolight’s CSO reflects on positive pre-clinical results and looks ahead to the next key milestone in Q2: Read the article here: https://biostock.se/2025/05/prolights-cso-reflects-on-positive-pre-clinical-results-and-looks-ahead-to-key-milestone-in-q2/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing […]
NOTICE OF THE ANNUAL GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), corp. reg. no. 556570-9499, (the ”Company”) are hereby notified of the annual general meeting to be held on Monday 30 June 2025 at 1 p.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification of attendance Shareholders who wish to participate in the annual general […]
Emergers publishes updated analysis about Prolight Diagnostics
Emergers publishes updated analysis about Prolight DIagnostics with the title: ”Gearing up for commercialisation with strong insider backing”. Among others, the article describes ”Strong insider commitment signals confidence” and that Prolight is ”Well-positioned for strategic partnering in 2025” Read the article here: https://www.emergers.se/prolight-j25/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: […]
NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), reg. no. 556570-9499, (the ”Company”) are hereby convened to the extraordinary general meeting to be held on Tuesday 10 June 2025 at 10 a.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification etc.Shareholders who wish to participate in the extraordinary general meeting must:– be […]
Prolight has resolved on a rights issue of shares to complete the development of the Point of Care system Psyros™ and reach commercialisation
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The […]
Prolight receives new MicroFlex patent approval in the US
Prolight announces today that the US Patent and Trademark Office (USPTO), pursuant to the notice of allowance issued on March 26, has granted Prolight a patent for the analytical unit and reaction chamber for the company’s point-of-care analysis system, MicroFlex, which is being developed by Prolight’s partner TTP (The Technology Partnership plc). This patent complements the […]
Study highlights speed of biomarker integration on Psyros POC platform
A collaborative research project between Prolight and St Thomas’ Hospital has demonstrated how quickly a cardiac biomarker assay for cMyC, can be transferred onto the Psyros™ point-of-care (POC) system. The study underscores the platform’s potential and its broader diagnostic applications beyond high-sensitive troponin. As part of Prolight’s on-going relationship with St Thomas’ Hospital, the Psyros™ […]
Prolight announces positive pre-clinical data
Prolight Diagnostics today announces positive results from the company’s pre-clinical validation study using plasma biobank samples. The results demonstrate that Prolight is on track to deliver its high-sensitivity troponin assay on the Psyros™ single-molecule-counting system. “The study results are highly encouraging and affirm the performance underlying the Psyros technology. Our system demonstrated very good clinical sensitivity […]
Prolight receives notice of allowance for MicroFlex patent
Prolight has received notice of allowance from the US Patent and Trademark Office (USPTO) for a patent application concerning the analytical device and reaction chamber for the company’s point-of-care system MicroFlex, in development by Prolight’s partner TTP (The Technology Partnership plc). The notice of allowance from USPTO means that the patent application is intended to be […]
The Psyros™ Cartridge Pilot Manufacturing line achieves another milestone!
Exciting developments are underway at FlexMedical Solutions with the arrival of new automation equipment to deliver our commitment to operational excellence, bringing us another step closer to large-scale production. We are proud of the hard work and collaboration between our teams and look forward to further strengthening our partnership as we move towards commercialization. Here’s a sneak […]
